Panmure Gordon tipped the x-ray specialist, which floated on AIM last month, to rise to 92p, giving it a stock market valuation of just under £100mln.
This values Amphion’s 11.6% stake at £11.5mln, which is almost £4mln higher than its current market capitalisation.
This did not go unnoticed by the investment community, who sent Amphion’s shares up 31% to 5.4p.
Since floating at 51p on October 16, Kromek’s shares have already risen 46% to 75p. At the current price, Amphion’s stake is worth £9.3mln.
Panmure’s Dr Mike Mitchell called Kromek “an enviably-placed business” and started covering the stock with a ‘buy’ rating.
“Its technology platform gives Kromek several ‘shots on goal’ in discrete high-value markets where there is already evidence of traction,” he said.
“With high-growth earnings targets, commercial execution will be key, and we anticipate delivery will justify a premium rating in due course.”